Tag Archives: cardiac safety

Cardiac Safety – the regulatory perspective

Dr Krishna Prasad, MHRA Proceedings from AHPPI’s conference on Risk Management in Early Phase Clinical Trials, 29 Oct 2015 (link).     Krishna reviewed the status quo pointing out that the regulations were a success in that no drugs having undergone E14 … Continue reading

Comments Off on Cardiac Safety – the regulatory perspective

Cardiac Safety – the industry perspective

Dr Boaz Mendzelevski, BioClinica Proceedings from AHPPI’s conference on Risk Management in Early Phase Clinical Trials, 29 Oct 2015 (link).     This year marks the 10th anniversary of the introduction of the ICH E14 guideline which was introduced to provide … Continue reading

Comments Off on Cardiac Safety – the industry perspective

Faculty conversation: TQT study – this is the end!

Recently, the FDA, other regulatory bodies, and pharmaceutical companies have been exploring options to replace TQTs with preclinical testing or with data collected during standard Phase I trials. Join colleagues from the FPM and also the British Pharmacological Society and … Continue reading

Comments Off on Faculty conversation: TQT study – this is the end!

Message from Chair: Presentations from the Joint Conference of European Human Pharmacological Societies

Dear Members, I have recently returned from a very successful and interesting International meeting in France held between the French (Club Phase 1), German (AGAH), Belgian (BAPU) and UK (AHPPI),human pharmacological societies.  The meeting was entitled EARLY CLINICAL UTILITY ASSESSMENT … Continue reading

0 Comments